Literature DB >> 30893266

The efficacy of a drug holiday test on two-stage revision for infected total knee arthroplasty.

Chun-Hung Chang1,2, Shang-Wen Tsai1,2, Kuei-Hsiang Hsu1,2, Ming-Chau Chang1,2, Wei-Ming Chen1,2, Yu-Ping Su1,2,3.   

Abstract

BACKGROUND: We compared the clinical efficacy of normal C-reactive protein (CRP) expression (<1.0 mg/dL), with a 2-week drug holiday test (DHT) and no drug holiday test (DHT) as a reimplantation criterion, based on subsequent infections after a two-stage revision of a total knee arthroplasty of a periprosthetic joint infection (PJI).
METHODS: In a 10-year review of 58 patients (mean age: 73.3-years-old; mean follow-up: 46.2 months), there were 31 patients in the DHT group and 27 patients in the DHT group. Primary outcome was recurrent infection rate. Secondary outcomes included length of hospital stay in the revision stage and CRP resurge one day before revision.
RESULTS: We reported that the CRP resurge rate in the DHT group (0%) was significantly (p = 0.029) lower than that in the DHT group (16.1%) one day before the revision. The DHT group also had a significantly shorter mean length of stay (LOS) in the hospital (9.6 vs 12.7 days, p = 0.015) and a nonsignificantly lower subsequent infection rate (14.8% vs 29%, p = 0.195).
CONCLUSION: We found that disciplined use of DHT as a reimplantation criterion reduced CRP resurges before reimplantation and yielded a shorter LOS afterward. DHT positively affected the subsequent mid-term infection rate after PJI treatment.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30893266     DOI: 10.1097/JCMA.0000000000000055

Source DB:  PubMed          Journal:  J Chin Med Assoc        ISSN: 1726-4901            Impact factor:   2.743


  1 in total

1.  Successful two-stage primary total knee arthroplasty for infective arthritis of the knee - our experience.

Authors:  Sam Supreeth; Suwailim Al Ghanami; Saseendar Shanmugasundaram; Raad Sabri Al Rawi; Ali Redha Abdawani; Shenouda R Abdelmasih
Journal:  J Clin Orthop Trauma       Date:  2020-07-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.